Copyright Reports & Markets. All rights reserved.

Global Compounded Bioidentical Hormone Therapy Market Growth 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Compounded Bioidentical Hormone Therapy Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Compounded Bioidentical Hormone Therapy by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Compounded Bioidentical Hormone Therapy by Country/Region, 2017, 2022 & 2028
  • 2.2 Compounded Bioidentical Hormone Therapy Segment by Type
    • 2.2.1 Oestrogen
    • 2.2.2 Progesterone
    • 2.2.3 Testosterone
  • 2.3 Compounded Bioidentical Hormone Therapy Sales by Type
    • 2.3.1 Global Compounded Bioidentical Hormone Therapy Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Compounded Bioidentical Hormone Therapy Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Compounded Bioidentical Hormone Therapy Sale Price by Type (2017-2022)
  • 2.4 Compounded Bioidentical Hormone Therapy Segment by Application
    • 2.4.1 Hospital Pharmacies
    • 2.4.2 Retail Pharmacies
    • 2.4.3 Online Pharmacies
    • 2.4.4 Others
  • 2.5 Compounded Bioidentical Hormone Therapy Sales by Application
    • 2.5.1 Global Compounded Bioidentical Hormone Therapy Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Compounded Bioidentical Hormone Therapy Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Compounded Bioidentical Hormone Therapy Sale Price by Application (2017-2022)

3 Global Compounded Bioidentical Hormone Therapy by Company

  • 3.1 Global Compounded Bioidentical Hormone Therapy Breakdown Data by Company
    • 3.1.1 Global Compounded Bioidentical Hormone Therapy Annual Sales by Company (2020-2022)
    • 3.1.2 Global Compounded Bioidentical Hormone Therapy Sales Market Share by Company (2020-2022)
  • 3.2 Global Compounded Bioidentical Hormone Therapy Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Compounded Bioidentical Hormone Therapy Revenue by Company (2020-2022)
    • 3.2.2 Global Compounded Bioidentical Hormone Therapy Revenue Market Share by Company (2020-2022)
  • 3.3 Global Compounded Bioidentical Hormone Therapy Sale Price by Company
  • 3.4 Key Manufacturers Compounded Bioidentical Hormone Therapy Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Compounded Bioidentical Hormone Therapy Product Location Distribution
    • 3.4.2 Players Compounded Bioidentical Hormone Therapy Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Compounded Bioidentical Hormone Therapy by Geographic Region

  • 4.1 World Historic Compounded Bioidentical Hormone Therapy Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Compounded Bioidentical Hormone Therapy Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Compounded Bioidentical Hormone Therapy Annual Revenue by Geographic Region
  • 4.2 World Historic Compounded Bioidentical Hormone Therapy Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Compounded Bioidentical Hormone Therapy Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Compounded Bioidentical Hormone Therapy Annual Revenue by Country/Region
  • 4.3 Americas Compounded Bioidentical Hormone Therapy Sales Growth
  • 4.4 APAC Compounded Bioidentical Hormone Therapy Sales Growth
  • 4.5 Europe Compounded Bioidentical Hormone Therapy Sales Growth
  • 4.6 Middle East & Africa Compounded Bioidentical Hormone Therapy Sales Growth

5 Americas

  • 5.1 Americas Compounded Bioidentical Hormone Therapy Sales by Country
    • 5.1.1 Americas Compounded Bioidentical Hormone Therapy Sales by Country (2017-2022)
    • 5.1.2 Americas Compounded Bioidentical Hormone Therapy Revenue by Country (2017-2022)
  • 5.2 Americas Compounded Bioidentical Hormone Therapy Sales by Type
  • 5.3 Americas Compounded Bioidentical Hormone Therapy Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Compounded Bioidentical Hormone Therapy Sales by Region
    • 6.1.1 APAC Compounded Bioidentical Hormone Therapy Sales by Region (2017-2022)
    • 6.1.2 APAC Compounded Bioidentical Hormone Therapy Revenue by Region (2017-2022)
  • 6.2 APAC Compounded Bioidentical Hormone Therapy Sales by Type
  • 6.3 APAC Compounded Bioidentical Hormone Therapy Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Compounded Bioidentical Hormone Therapy by Country
    • 7.1.1 Europe Compounded Bioidentical Hormone Therapy Sales by Country (2017-2022)
    • 7.1.2 Europe Compounded Bioidentical Hormone Therapy Revenue by Country (2017-2022)
  • 7.2 Europe Compounded Bioidentical Hormone Therapy Sales by Type
  • 7.3 Europe Compounded Bioidentical Hormone Therapy Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Compounded Bioidentical Hormone Therapy by Country
    • 8.1.1 Middle East & Africa Compounded Bioidentical Hormone Therapy Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Compounded Bioidentical Hormone Therapy Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Compounded Bioidentical Hormone Therapy Sales by Type
  • 8.3 Middle East & Africa Compounded Bioidentical Hormone Therapy Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Compounded Bioidentical Hormone Therapy
  • 10.3 Manufacturing Process Analysis of Compounded Bioidentical Hormone Therapy
  • 10.4 Industry Chain Structure of Compounded Bioidentical Hormone Therapy

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Compounded Bioidentical Hormone Therapy Distributors
  • 11.3 Compounded Bioidentical Hormone Therapy Customer

12 World Forecast Review for Compounded Bioidentical Hormone Therapy by Geographic Region

  • 12.1 Global Compounded Bioidentical Hormone Therapy Market Size Forecast by Region
    • 12.1.1 Global Compounded Bioidentical Hormone Therapy Forecast by Region (2023-2028)
    • 12.1.2 Global Compounded Bioidentical Hormone Therapy Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Compounded Bioidentical Hormone Therapy Forecast by Type
  • 12.7 Global Compounded Bioidentical Hormone Therapy Forecast by Application

13 Key Players Analysis

  • 13.1 SottoPelle
    • 13.1.1 SottoPelle Company Information
    • 13.1.2 SottoPelle Compounded Bioidentical Hormone Therapy Product Offered
    • 13.1.3 SottoPelle Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 SottoPelle Main Business Overview
    • 13.1.5 SottoPelle Latest Developments
  • 13.2 BioTE Medical
    • 13.2.1 BioTE Medical Company Information
    • 13.2.2 BioTE Medical Compounded Bioidentical Hormone Therapy Product Offered
    • 13.2.3 BioTE Medical Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 BioTE Medical Main Business Overview
    • 13.2.5 BioTE Medical Latest Developments
  • 13.3 Advantage Pharmaceuticals
    • 13.3.1 Advantage Pharmaceuticals Company Information
    • 13.3.2 Advantage Pharmaceuticals Compounded Bioidentical Hormone Therapy Product Offered
    • 13.3.3 Advantage Pharmaceuticals Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Advantage Pharmaceuticals Main Business Overview
    • 13.3.5 Advantage Pharmaceuticals Latest Developments
  • 13.4 Full Life Wellness Center
    • 13.4.1 Full Life Wellness Center Company Information
    • 13.4.2 Full Life Wellness Center Compounded Bioidentical Hormone Therapy Product Offered
    • 13.4.3 Full Life Wellness Center Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Full Life Wellness Center Main Business Overview
    • 13.4.5 Full Life Wellness Center Latest Developments
  • 13.5 Neuva Aesthetics
    • 13.5.1 Neuva Aesthetics Company Information
    • 13.5.2 Neuva Aesthetics Compounded Bioidentical Hormone Therapy Product Offered
    • 13.5.3 Neuva Aesthetics Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Neuva Aesthetics Main Business Overview
    • 13.5.5 Neuva Aesthetics Latest Developments
  • 13.6 Defy Medical
    • 13.6.1 Defy Medical Company Information
    • 13.6.2 Defy Medical Compounded Bioidentical Hormone Therapy Product Offered
    • 13.6.3 Defy Medical Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Defy Medical Main Business Overview
    • 13.6.5 Defy Medical Latest Developments
  • 13.7 Bio station
    • 13.7.1 Bio station Company Information
    • 13.7.2 Bio station Compounded Bioidentical Hormone Therapy Product Offered
    • 13.7.3 Bio station Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Bio station Main Business Overview
    • 13.7.5 Bio station Latest Developments
  • 13.8 Noven Pharmaceuticals
    • 13.8.1 Noven Pharmaceuticals Company Information
    • 13.8.2 Noven Pharmaceuticals Compounded Bioidentical Hormone Therapy Product Offered
    • 13.8.3 Noven Pharmaceuticals Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Noven Pharmaceuticals Main Business Overview
    • 13.8.5 Noven Pharmaceuticals Latest Developments
  • 13.9 Novartis AG
    • 13.9.1 Novartis AG Company Information
    • 13.9.2 Novartis AG Compounded Bioidentical Hormone Therapy Product Offered
    • 13.9.3 Novartis AG Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 Novartis AG Main Business Overview
    • 13.9.5 Novartis AG Latest Developments
  • 13.10 Pfizer
    • 13.10.1 Pfizer Company Information
    • 13.10.2 Pfizer Compounded Bioidentical Hormone Therapy Product Offered
    • 13.10.3 Pfizer Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 Pfizer Main Business Overview
    • 13.10.5 Pfizer Latest Developments
  • 13.11 TherapeuticsMD
    • 13.11.1 TherapeuticsMD Company Information
    • 13.11.2 TherapeuticsMD Compounded Bioidentical Hormone Therapy Product Offered
    • 13.11.3 TherapeuticsMD Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 TherapeuticsMD Main Business Overview
    • 13.11.5 TherapeuticsMD Latest Developments
  • 13.12 Bayer AG
    • 13.12.1 Bayer AG Company Information
    • 13.12.2 Bayer AG Compounded Bioidentical Hormone Therapy Product Offered
    • 13.12.3 Bayer AG Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 Bayer AG Main Business Overview
    • 13.12.5 Bayer AG Latest Developments
  • 13.13 Novo Nordisk
    • 13.13.1 Novo Nordisk Company Information
    • 13.13.2 Novo Nordisk Compounded Bioidentical Hormone Therapy Product Offered
    • 13.13.3 Novo Nordisk Compounded Bioidentical Hormone Therapy Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 Novo Nordisk Main Business Overview
    • 13.13.5 Novo Nordisk Latest Developments

14 Research Findings and Conclusion

As the global economy mends, the 2021 growth of Compounded Bioidentical Hormone Therapy will have significant change from previous year. According to our (LP Information) latest study, the global Compounded Bioidentical Hormone Therapy market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Compounded Bioidentical Hormone Therapy market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.

The United States Compounded Bioidentical Hormone Therapy market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Compounded Bioidentical Hormone Therapy market, reaching US$ million by the year 2028. As for the Europe Compounded Bioidentical Hormone Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.

Global main Compounded Bioidentical Hormone Therapy players cover SottoPelle, BioTE Medical, Advantage Pharmaceuticals, and Full Life Wellness Center, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Compounded Bioidentical Hormone Therapy market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Oestrogen
Progesterone
Testosterone

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
SottoPelle
BioTE Medical
Advantage Pharmaceuticals
Full Life Wellness Center
Neuva Aesthetics
Defy Medical
Bio station
Noven Pharmaceuticals
Novartis AG
Pfizer
TherapeuticsMD
Bayer AG
Novo Nordisk
Buy now